Factor VIII gene therapy - Corautus Genetics

Drug Profile

Factor VIII gene therapy - Corautus Genetics

Alternative Names: Factor VIII MAXIMUM-AD; MAX-AD Factor VIII gene therapy

Latest Information Update: 09 Apr 2003

Price : $50

At a glance

  • Originator Baxter Healthcare Corporation; Corautus Genetics
  • Class Blood coagulation factors; Coagulants
  • Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Haemophilia A

Most Recent Events

  • 20 Feb 2003 GenStar Therapeutics Corporation has merged with Vascular Genetics to form Corautus Genetics
  • 17 Feb 2003 Discontinued - Phase-I for Haemophilia A in USA (Parenteral)
  • 18 Jun 2002 Further preclinical results have been added to the pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top